=Pricing and Reimbursement=
Pricing and reimbursement systems in Singapore are transparent and straightforward. Drug pricing is leftto market forces in the private sector, while, in the public sector, drugs are divided into two categories:‘standard’ and ‘non-standard’ drugs. Only the former are subsidised by the government, as the latter arepredominantly used in the private sector. The obligation of public hospitals to use generics whereavailable restricts the market for original products to drugs without a generic equivalent and the privatesector, while tendering reflects negatively on pharmaceutical values.
シンガポールの価格設定及び償還制度は明白で分かりやすい。民間部門での医薬品の価格設定は市場動向に委ねられているが、公的部門においては、医薬品は「標準品」及び「非標準品」の2つのカテゴリーに分けられている。政府の補助金が適用されるのは「標準品」のみで、それは「非標準品」が圧倒的に民間部門で用いられているからだ。公立病院に入手可能な後発医薬品の使用を義務づけることは、先発医薬品の需要を後発同等医薬品のない医薬品および民間部門に限定するが、入札制度は医薬品の価値に悪い影響を与える。
Although the pricing and reimbursement systems are generally looked upon favourably by theinternational drug industry, recent proposals for changes in the regimes have caused some concern. Thegovernment has revealed its intention to reduce price levels in the country in a bid to contain rising levelsof public expenditure on healthcare and pharmaceuticals, which has worsened with the progress ofpopulation ageing and higher patient demands. Methods currently under consideration include theexpansion of parallel trade, and greater collaboration between the public and private sectors.
The above measures, especially the former, are likely to put considerable pressure on multinational profitmargins, as it facilitates the entry of a large number of cheap medicines on to the market. However, as thechanges have been under discussion for some time, multinational pressure and the government’s desire toattract foreign investment may have contributed to slower-than-expected progress in this area. Given thatthis situation is unlikely to change in the short term, it can be assumed that such alterations will remain atthe proposal stage, for the time being.
公立病院に入手可能な後発医薬品の使用を義務づけることは、先発医薬品の需要を後発同等医薬品のない医薬品および民間部門に限定するが、入札制度は医薬品の価値に悪い影響を与える。
日本語として意味がまったく通じないです。
申し訳ありません、以下書き換えましたが、少しは意味が通じるでしょうか?
「公立病院に対し後発医薬品がある場合にはそれらを使用させる義務づけによって、先発医薬品の市場は後発医薬品がまだない場合および民間部門への販売のみに限られる一方で、入札制度は医薬品の価格価値を下げるというネガティブな影響を与える。」